List of Excipients in Branded Drug RECTIV

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ProStrakan Inc	RECTIV	nitroglycerin	42747-235	LANOLIN
ProStrakan Inc	RECTIV	nitroglycerin	42747-235	PARAFFIN
ProStrakan Inc	RECTIV	nitroglycerin	42747-235	PETROLATUM
ProStrakan Inc	RECTIV	nitroglycerin	42747-235	PROPYLENE GLYCOL
ProStrakan Inc	RECTIV	nitroglycerin	42747-235	SORBITAN SESQUIOLEATE
Allergan Inc	RECTIV	nitroglycerin	58914-301	LANOLIN

RECTIV Excipient Strategy and Commercial Opportunities for Nitroglycerin 0.4% Ointment

Last updated: September 24, 2026

Rectiv is a topical nitroglycerin 0.4% ointment approved for short-term treatment of moderate-to-severe pain associated with chronic anal fissure in adults. Its commercial value is driven less by active-ingredient novelty than by formulation performance, patient tolerability, metered dosing, packaging, and regulatory execution. The principal opportunities are generic entry, authorized-generic supply, improved-dose delivery, preservative-free or allergen-reduced formulations, and international licensing.

The reference formulation uses a hydrophobic ointment base containing white petrolatum, paraffin, propylene glycol, lanolin and sorbitan sesquioleate. These excipients support drug dispersion, skin contact, spreadability and dose delivery, but they also create opportunities for differentiated products addressing lanolin sensitivity, messiness, dosing variability and packaging losses. [1]

What is Rectiv and how does its formulation work?

Rectiv contains nitroglycerin at a concentration of 0.4% for anorectal administration. The labeled dose is 1 inch of ointment, corresponding to approximately 375 mg of ointment and about 1.5 mg of nitroglycerin, applied intra-anally every 12 hours for up to three weeks. [1]

What excipients are used in Rectiv?

The labeled inactive ingredients are:

Excipient	Likely formulation function
White petrolatum	Primary occlusive ointment base; improves lubrication and skin contact
Paraffin	Viscosity control, structure and emollience
Lanolin	Emollient and adhesion enhancer; may improve skin feel
Propylene glycol	Cosolvent, humectant and penetration-supporting excipient
Sorbitan sesquioleate	Lipophilic emulsifier and dispersion aid

The formulation is substantially anhydrous and oil-based. That design is commercially relevant because an anhydrous ointment can reduce microbial-growth concerns compared with a water-containing cream, while providing prolonged contact with the anoderm. It also creates constraints around nitroglycerin uniformity, volatility, packaging compatibility, skin irritation and dose reproducibility.

Why is the ointment base commercially important?

For Rectiv, the excipient system is part of the product’s clinical performance. A formulation must maintain:

• Uniform nitroglycerin distribution throughout the tube.
• Consistent delivery from the first dose through the final dose.
• Adequate adhesion to the anorectal mucosa.
• Sufficient spreadability without excessive leakage.
• Chemical stability during storage.
• Acceptable skin and mucosal tolerability.
• Compatibility with the tube, liner, applicator and closure.

A generic product that contains the same concentration of nitroglycerin but changes the base may face questions about comparative performance, product quality and, depending on the regulatory route, therapeutic equivalence.

What formulation patents protect Rectiv?

Rectiv’s commercial protection is primarily associated with the use of topical nitroglycerin for anal fissure and the approved drug product rather than with a new molecular entity. Nitroglycerin has been used clinically for decades, and the active ingredient itself is not a meaningful source of modern exclusivity.

Does Rectiv have active-ingredient patent protection?

No meaningful composition-of-matter protection should be expected for nitroglycerin. The relevant intellectual-property issues are more likely to involve:

• Method-of-use claims for treating anal fissure pain.
• Specific nitroglycerin concentrations.
• Ointment or topical delivery systems.
• Dosing schedules.
• Packaging or applicator configurations.
• Manufacturing and content-uniformity processes.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with an approved drug product. A commercial diligence review should distinguish Orange Book-listed patents from expired patents, unlisted formulation know-how and patents held by parties other than the NDA holder. [2]

What is the Orange Book status of Rectiv?

Rectiv was approved under NDA 022254. FDA product databases and the Orange Book should be reviewed for the current marketing status, listed patents, pediatric exclusivity, and any approved ANDAs. [2,3]

The main commercial conclusion is that Rectiv is unlikely to have a durable barrier based solely on nitroglycerin chemistry. Any remaining protection is more likely to be narrow, expired, product-specific or dependent on formulation and regulatory differences.

When does Rectiv lose exclusivity?

Rectiv’s market exclusivity depends on the type of protection involved:

Protection category	Commercial relevance
Nitroglycerin composition patent	No practical modern barrier expected
Method-of-use patent	Potentially relevant to labeling and Paragraph IV litigation
Formulation patent	Relevant if valid, unexpired and listed or otherwise enforceable
NDA regulatory exclusivity	Depends on FDA designation and approval history
Trade secrets	May cover mixing, filling, stability and packaging processes
Trademark	Rectiv brand rights may remain even after generic entry

FDA approval does not itself create permanent protection. Once applicable regulatory exclusivity and enforceable patent barriers expire, an ANDA applicant can seek approval for a therapeutically equivalent nitroglycerin ointment.

Are Paragraph IV challenges likely for Rectiv?

A Paragraph IV strategy would be commercially plausible if an applicant identifies an unexpired listed patent covering the product, its use or its formulation. The applicant would need to certify that the patent is invalid, unenforceable or will not be infringed. [3,4]

For a topical ointment, the principal challenge is not only patent validity. The applicant must also establish pharmaceutical equivalence and bioequivalence under FDA requirements applicable to the product. A generic developer may prefer:

1. A Paragraph III certification if a patent remains but has a defined expiration date.
2. A Paragraph IV certification if the patent is considered vulnerable.
3. A suitability petition or other abbreviated pathway if the proposed product differs in dosage form or composition.
4. A 505(b)(2) application for a materially different formulation or delivery system. [4,5]

What excipient strategy is best for a Rectiv generic?

The lowest-risk strategy is to replicate the reference product’s critical formulation attributes while avoiding unnecessary excipient changes. The development program should focus on equivalence, dose uniformity and container-closure compatibility rather than adding cosmetic complexity.

Strategy 1: Reference-matched ointment

A reference-matched product would use the same active concentration and a closely comparable hydrophobic base. Its advantages are:

• Lower formulation risk.
• Easier justification of pharmaceutical equivalence.
• Familiar spreadability and patient use profile.
• Lower clinical differentiation burden.
• Better prospects for a conventional ANDA pathway.

The main disadvantages are limited product differentiation and exposure to price competition.

Strategy 2: Lanolin-reduced or lanolin-free ointment

Lanolin can cause allergic contact dermatitis in susceptible patients. A lanolin-free product could target patients with documented sensitivity or clinicians seeking a simpler excipient profile.

The commercial challenge is that removing lanolin can change:

• Ointment structure.
• Adhesion.
• Spreadability.
• Drug distribution.
• Skin feel.
• Release characteristics.

A lanolin-free product should not be treated as a simple substitution. The developer would need comparative performance testing and a regulatory assessment of whether the change remains suitable for an ANDA or requires a 505(b)(2) pathway.

Strategy 3: Metered-dose delivery

Rectiv’s labeled dose is based on a measured length of ointment. A metered applicator, unit-dose sachet or calibrated nozzle could reduce dose variability and improve patient handling.

Potential advantages include:

• More consistent delivered dose.
• Lower contamination risk.
• Improved adherence.
• Better pharmacy counseling.
• Premium positioning for a branded generic.

Potential barriers include device qualification, extractables and leachables, dose accuracy, package integrity, human-factors work and combination-product considerations.

Strategy 4: Lower-mess formulation

Patient dissatisfaction with oily residue, leakage and application difficulty is a plausible commercial weakness of an ointment. A gel, cream, emulgel or mucoadhesive system could improve user experience.

Such a product would have a higher regulatory burden because changes in water content, rheology, release and mucosal residence time may affect local performance. The commercial opportunity is greater, but the product may require a 505(b)(2) application rather than a straightforward generic route.

What manufacturing and IP barriers affect Rectiv?

Manufacturing barriers are moderate. The active ingredient is established, but nitroglycerin requires careful handling because of its pharmacologic potency, occupational exposure concerns and sensitivity to process controls.

Which manufacturing steps are most important?

Key controls include:

• Accurate weighing and controlled incorporation of nitroglycerin.
• Homogeneous distribution in the ointment base.
• Prevention of localized high-concentration areas.
• Control of mixing temperature and shear.
• Tube-filling uniformity.
• Compatibility between formulation and packaging.
• Stability monitoring for assay, impurities and physical changes.
• Protection from heat, light and inappropriate storage conditions.

The product’s commercial risk is concentrated in content uniformity and packaging rather than in synthesis of the active ingredient. A manufacturer with established handling capability for potent vasodilators or transdermal nitroglycerin may have an operational advantage.

Can packaging create a defensible position?

Yes. Packaging can support differentiation even when the formulation is not strongly patentable. Potential positions include:

• Calibrated dose-marked tubes.
• Single-use foil sachets.
• Low-loss dispensing systems.
• Child-resistant closures.
• Improved moisture and oxygen barriers.
• Applicators designed for hygienic anorectal administration.

Packaging patents may be narrower than formulation patents, but commercial execution can still create switching costs if the device improves dosing and adherence.

What FDA regulatory pathway applies to new Rectiv products?

The pathway depends on how closely the proposed product matches the reference product.

Proposed product	Likely regulatory approach
Same strength, dosage form and route with comparable inactive ingredients	ANDA
Same active ingredient with a materially different base or device	505(b)(2) may be appropriate
New concentration or dosing regimen	505(b)(2) or full development program
New indication	505(b)(2) or supplemental NDA
Combination of nitroglycerin with another active	NDA or 505(b)(2)

For a conventional generic, the developer must address pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls, labeling and device or packaging differences. FDA’s product-specific guidance and ANDA requirements should govern the development plan. [4,5]

What commercial opportunities exist for Rectiv?

Generic and authorized-generic opportunity

A conventional generic can compete on:

• Wholesale acquisition cost.
• Payer coverage.
• Pharmacy availability.
• Supply reliability.
• Tube size and dispensing convenience.

Because anal fissure is a niche indication, the market may support only a limited number of suppliers before price erosion becomes severe. A manufacturer with an efficient small-batch sterile or semisolid operation may have an advantage over larger companies that require higher volume.

Branded-generic opportunity

A branded generic could command a premium through:

• Dose-calibrated packaging.
• Lanolin-free positioning.
• Improved applicator design.
• Patient instruction materials.
• Specialty-pharmacy distribution.
• Supply guarantees for colorectal and gastroenterology practices.

The commercial case depends on whether the product can demonstrate a meaningful reduction in dose variability or administration burden.

Contract manufacturing and licensing

Rectiv-related opportunities exist for:

• Licensing a generic formulation to a regional pharmaceutical company.
• Supplying private-label nitroglycerin ointment.
• Contract manufacturing for specialty-generic companies.
• Licensing a metered-delivery device.
• Regional rights for markets where anal fissure products are fragmented.

A licensing agreement would likely place greater value on regulatory readiness, stability data and manufacturing scale than on broad patent ownership.

International expansion

Outside the United States, topical nitroglycerin products may be regulated under different national pathways. Opportunities include:

• Local registration of a generic ointment.
• Transfer of a U.S.-validated formulation.
• Partnerships with colorectal or hospital-focused companies.
• Adaptation to country-specific packaging and labeling rules.

Geographic expansion must account for local rules governing prescription status, excipient acceptability, nitroglycerin handling, device claims and reference-product requirements.

How strong is the Rectiv patent estate?

The estate appears structurally weaker than the estate for a protected new chemical entity because:

• Nitroglycerin is old and widely known.
• The dosage form is a conventional topical ointment.
• The commercial differentiation is formulation- and device-dependent.
• Any method-of-use claims may be vulnerable to prior-art arguments.
• Generic entry can focus on an alternative excipient composition if the reference formulation is not broadly protected.

The strongest defensible positions are likely to be narrow claims directed to a specific excipient ratio, release profile, dose-delivery system, packaging configuration or manufacturing process. Those claims must survive validity, infringement and enablement scrutiny.

What litigation and settlement issues affect Rectiv?

A Rectiv generic dispute could involve:

• Paragraph IV certification.
• Patent-owner suit within the Hatch-Waxman litigation window.
• Claims directed to anal-fissure treatment.
• Arguments over whether the generic label induces infringement.
• Equivalence of ointment composition and delivery.
• Automatic stay implications for FDA approval.
• Potential 180-day first-filer exclusivity.

Settlement terms could include a licensed entry date, supply agreement, authorized-generic arrangement or restrictions tied to a specific formulation. No commercial decision should rely on a settlement assumption without reviewing the court docket, FDA correspondence and the actual agreement terms.

How does Rectiv compare with compounded nitroglycerin?

Compounded nitroglycerin ointment may compete on local availability and price, but it is not automatically equivalent to an FDA-approved product. Differences may occur in:

• Nitroglycerin concentration.
• Base composition.
• Dose uniformity.
• Stability dating.
• Packaging.
• Prescriber confidence.
• Pharmacy quality systems.

An FDA-approved generic can differentiate from compounding pharmacies through validated manufacturing, standardized labeling, commercial distribution and consistent quality documentation. Compounding remains a price and access risk in markets where patients have difficulty obtaining branded or generic product.

What generic launch scenarios exist?

Scenario	Market effect
One approved generic	Moderate price pressure; brand may retain specialty prescribers
Two to three generics	Rapid payer-driven substitution and lower net pricing
Multiple low-cost suppliers	Commodity pricing and supply volatility
Premium device-based generic	Smaller share with higher gross margin
505(b)(2) reformulation	Differentiated pricing but higher development cost
Authorized generic	Faster brand defense and additional channel control

Rectiv’s niche volume makes reliable supply especially important. A shortage or discontinuation can create temporary pricing power, but that advantage is difficult to sustain without manufacturing redundancy.

Key Takeaways

• Rectiv is nitroglycerin 0.4% ointment for adult chronic anal fissure pain.
• Its excipient system includes white petrolatum, paraffin, lanolin, propylene glycol and sorbitan sesquioleate.
• The core commercial issues are dose uniformity, mucosal adhesion, tolerability, packaging and patient administration.
• A reference-matched generic has the lowest regulatory risk but limited differentiation.
• Lanolin-free, metered-dose and lower-mess formulations offer stronger commercial positioning.
• A materially different formulation may require a 505(b)(2) strategy rather than a conventional ANDA.
• Nitroglycerin itself is not a meaningful source of modern composition-of-matter exclusivity.
• The strongest potential IP positions are narrow formulation, device, packaging and manufacturing claims.
• Generic competition is likely to produce rapid price erosion in a small prescription market.
• Licensing and contract manufacturing may offer better returns than a standalone branded relaunch.

FAQs

Is Rectiv the same as nitroglycerin ointment compounded by a pharmacy?

No. Rectiv is an FDA-approved product with defined strength, labeling, manufacturing controls and packaging. Compounded products may use different bases, concentrations, stability periods and dispensing systems.

Can a lanolin-free nitroglycerin ointment be approved as a generic?

Possibly, but the excipient change must be assessed for its effect on drug distribution, release, adhesion, tolerability and equivalence. A material formulation difference may make a 505(b)(2) application more appropriate.

Does a metered applicator create patentable value for Rectiv?

It can create patent and commercial value if the device provides a novel, non-obvious mechanism for dose measurement, delivery, contamination control or package compatibility. Device claims would remain separate from protection for nitroglycerin itself.

Is Rectiv a strong candidate for an authorized generic?

Yes, if the brand owner controls reliable manufacturing or can license the product to a generic company. An authorized generic can protect distribution, retain payer access and respond to independent generic entry.

What is the most attractive formulation opportunity for Rectiv?

The strongest balance of commercial differentiation and technical feasibility is a dose-calibrated, lanolin-reduced or lanolin-free ointment with validated content uniformity and improved patient handling. A fully redesigned gel or emulgel could offer more differentiation but would carry greater regulatory and development risk.

References

1. U.S. Food and Drug Administration. (2007). Rectiv (nitroglycerin) ointment, 0.4% prescribing information. NDA 022254.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

5. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. https://www.fda.gov/drugs/types-applications/505b2-application-productions-containing-new-drug-substances